Inicio・Lista de Acciones・REGENXBIO Inc

REGENXBIO Inc

Cerrado

SectorSanidad

10.38 -0.48

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

9.86

Máximo

10.47

Métricas clave
By Trading Economics
Ingresos	-23M -90M
Ventas	-24M 6.4M
BPA	-1.72
Margen de beneficios	-1,408.588
Empleados	371
EBITDA	-14M -77M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+102.42% upside

Dividendos
By Acuity
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	201M 721M
Apertura anterior	10.86
Cierre anterior	10.38

Noticias sobre sentimiento de mercado

By Acuity

17%

83%

24 / 340 Clasificación en Healthcare

REGENXBIO Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 jul 2026, 19:31 UTC

Event

News

Social Media

Regenxbio shares rise after positive long-term trial results for surabgene lomparvovec, showing sustained vision improvements in patients with retinal conditions.

Comparación entre iguales

Cambio de precio

REGENXBIO Inc previsión

Precio Objetivo

By TipRanks

102.42% repunte

Estimación a 12 Meses

Media 20.89 USD 102.42%

Máximo 42 USD

Mínimo 10 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para REGENXBIO Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para REGENXBIO Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

24 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.